🟠 Moderate Evidence
The MTHFR gene has become a fixture of consumer wellness discourse, with most attention directed toward methylfolate supplementation. Yet clinical trial evidence suggests the real therapeutic opportunity lies elsewhere: riboflavin (vitamin B2) supplementation in carriers of the C677T TT variant, a genetic polymorphism present in approximately 10% of European and US populations, according to trials conducted by researchers at Ulster University.
Key takeaways
- The MTHFR C677T TT variant, carried by roughly 10% of Europeans and Americans, produces a thermolabile enzyme variant that loses its critical cofactor more readily
- In hypertensive patients with the TT genotype, 1.6 mg daily riboflavin for 16 weeks reduced systolic blood pressure by 13 mmHg — a clinically meaningful effect achieved at near-dietary doses
- The effect was completely genotype-specific; CC and CT carriers showed no response, suggesting precision medicine potential
- Only 37% of untreated TT carriers on antihypertensive medication achieved target blood pressure, compared to 64% of CC carriers — a treatment-resistant gap that riboflavin supplementation appeared to close
Study at a Glance
| Primary source | Horigan et al., published trial data from Ulster University research group |
| Study design | Randomized controlled trial with genotype stratification and 4-year follow-up cohort |
| Sample population | Hypertensive patients with documented cardiovascular disease; secondary trial in hypertensive patients without overt CVD |
| Intervention | 1.6 mg riboflavin daily for 16 weeks |
| Primary outcome | Systolic blood pressure reduction in C677T TT carriers |
| Geographic scope | United Kingdom (Ulster University) |
Blood Pressure Response by MTHFR Genotype: Riboflavin Trial Results
Systolic BP change and medication response rates in hypertensive patients, stratified by C677T variant carrier status
Source: Horigan et al. trial data; Ulster University | Georgian Medical Journal News
The biochemistry behind the gene-variant effect
MTHFR (methylenetetrahydrofolate reductase) is an enzyme responsible for converting one form of folate into another — a critical step in one-carbon metabolism and homocysteine regulation. The enzyme requires a cofactor called FAD (flavin adenine dinucleotide), which the body synthesizes from riboflavin (vitamin B2).
The C677T TT variant, one of several MTHFR polymorphisms, produces a thermolabile (heat-sensitive) version of the enzyme. This variant-encoded enzyme loses its FAD cofactor more readily than the wild-type form, rendering it functionally compromised. When dietary riboflavin intake is insufficient, the enzyme underperforms, homocysteine accumulates, and vascular endothelial function deteriorates, driving blood pressure elevation.
This mechanistic pathway explains why the therapeutic intervention targets B2 restoration rather than methylfolate supplementation — a distinction that has been largely lost in consumer wellness discourse, according to the Clinical Updates section at Georgian Medical Journal News.
Clinical trial evidence: genotype-specific blood pressure response
In a landmark trial, Horigan et al. examined the blood pressure response to riboflavin supplementation in hypertensive patients with cardiovascular disease, stratified by MTHFR C677T genotype. TT carriers received 1.6 mg riboflavin daily for 16 weeks. The result was striking: systolic blood pressure fell from 144 mmHg to 131 mmHg — a 13 mmHg reduction. Crucially, CC and CT carriers showed no meaningful change, confirming the effect was genotype-specific.
A subsequent trial by Wilson et al. followed the original TT-carrier cohort for four years, demonstrating that the blood pressure-lowering effect was sustained with continued supplementation. An independent trial by the same research group replicated the effect in hypertensive patients without documented overt cardiovascular disease, broadening the applicability of the finding.
The clinical significance emerges when comparing treatment response rates. Among TT carriers on standard antihypertensive medication, only 37% achieved target blood pressure (
Dosing, mechanism, and the evidence gap
Across all trials, the therapeutic dose was 1.6 mg riboflavin daily — essentially at the upper boundary of the recommended dietary allowance (1.1–1.3 mg for adults) and well below what would be considered a megadose intervention. This proximity to dietary recommendations suggests the mechanism is cofactor restoration rather than pharmacological intervention, a distinction with implications for clinical adoption and patient safety.
The primary limitation of the current evidence base is its narrow research origin. The substantial body of trial data supporting riboflavin efficacy derives almost entirely from a single research group at Ulster University. While the individual trial methodology is rigorous and the proposed biochemical mechanism is well-established, independent replication by geographically and institutionally diverse research teams remains absent. As noted in the New Studies section at GMJ News, single-group evidence — however mechanistically sound — typically requires external validation before influencing clinical practice guidelines.
In MTHFR C677T TT carriers with hypertension, 1.6 mg daily riboflavin for 16 weeks reduced systolic blood pressure by 13 mmHg and appeared to overcome treatment resistance that affects the majority of genotypically untreated carriers.
— Horigan et al., Ulster University
What this means
Frequently asked questions
Is MTHFR genotyping routinely available in clinical practice?
MTHFR C677T genotyping is widely available through clinical laboratories and direct-to-consumer genetic testing. However, interpretation and clinical integration remain inconsistent. The genotype test itself is straightforward; clinical application is the limiting factor. Discuss with your healthcare provider whether genotyping is appropriate for your cardiovascular risk profile.
Why do most wellness discussions focus on methylfolate instead of riboflavin?
Methylfolate supplementation became popular based on theoretical logic: if MTHFR converts folate, why not give the “active” form directly? However, clinical trial evidence for methylfolate in MTHFR carriers is sparse and inconsistent, while riboflavin evidence is mechanistically sound and clinically validated in the hypertension phenotype. The wellness narrative often prioritizes plausibility over clinical data.
Are there safety concerns with 1.6 mg daily riboflavin?
No. This dose is well within safe intake ranges; riboflavin is water-soluble and excess amounts are excreted. The recommended dietary allowance is 1.1–1.3 mg; the therapeutic dose used in trials (1.6 mg) represents only a modest overage. Riboflavin is non-toxic at supplemental doses up to several hundred milligrams daily.
The MTHFR story exemplifies how precision medicine can emerge from the intersection of molecular biology, genotyping, and rigorous clinical trial design. Yet it also illustrates the persistence gap between mechanistic evidence and clinical implementation. As the wellness industry continues amplifying discussion of MTHFR, the real clinical opportunity — genotype-guided riboflavin supplementation for treatment-resistant hypertension — remains underexplored. Independent replication of the Ulster University trials across diverse patient populations and healthcare systems will be essential to determine whether this finding represents a reproducible, generalizable precision medicine intervention or an artifact of a single research program. For patients seeking evidence-based guidance on nutrition and supplements, the distinction matters.
Source: Horigan et al. and Wilson et al. trials, Ulster University; MTHFR C677T polymorphism prevalence data from European and US population genetics literature
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
